Needham Reiterates Buy Rating for Neumora Therapeutics
Needham maintains its positive outlook on Neumora Therapeutics, setting a $5.00 price target.
Key Points
- Needham reiterated its buy rating on Neumora Therapeutics with a $5.00 price target on June 16, 2026.
- Neumora Therapeutics, traded as NMRA on NasdaqGS, has a market cap of $289 million and a 52-week range of $0.716 to $3.65.
- Recent insider activity includes multiple purchases of 80,000 shares each by executives on May 27, 2026.
On June 16, 2026, Needham reiterated its buy rating for Neumora Therapeutics, Inc. (NasdaqGS: NMRA), setting a price target of $5.00. The analyst, Ami Fadia, continues to see potential in the company's pipeline of treatments for brain diseases and neuropsychiatric disorders.
Other Institutional Activity in Neumora Therapeutics
SIREN, L.L.C. significantly increased its holdings in Neumora, adding 2,209,039 shares to reach a total of 8,497,822 shares valued at about $16.57 million. SOFTBANK GROUP CORP. reduced its stake by 339,419 shares, ending with 6,090,301 shares worth approximately $11.88 million. Perceptive Advisors LLC initiated a position with 5,104,097 shares, valued at nearly $9.95 million. Meanwhile, MIC Capital Management UK LLP maintained its position, holding 4,460,700 shares valued at $8.70 million.
Neumora Therapeutics Stock Snapshot
Shares of Neumora Therapeutics (NasdaqGS: NMRA) traded around $0.914. The company has a market cap of approximately $289 million and a beta of 2.759, indicating high volatility. The stock's 52-week range spans from $0.716 to $3.65, with a 50-day moving average of $1.9523 and a 200-day moving average of $2.195375. Neumora has a current ratio of 5.095 and a quick ratio of 4.884, with a debt-to-equity ratio of 75.514.
Insider Buying and Selling at Neumora Therapeutics, Inc.
On May 27, 2026, several insiders at Neumora Therapeutics, including Matthew Fust, Maykin Ho, Kristina Burow, Alaa Halawa, and David Piacquad, each purchased 80,000 shares. These transactions were not part of any pre-planned trading program. Additionally, on February 17, 2026, Michael Lee Milligan, the Chief Financial Officer, sold 1,436 shares at an average price of $3.565.
Analysts Set New Price Targets
On June 16, 2026, Needham maintained its buy rating for Neumora Therapeutics with a $5.00 price target. The same day, HC Wainwright & Co. also maintained a buy rating, setting a higher target of $7.00. Overall, the consensus among analysts is a buy, with a mean price target of $8.91 based on eight analyst opinions.
About Neumora Therapeutics
Neumora Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, focused on developing treatments for brain-related diseases. The company's lead product, navacaprant (NMRA-140), is in phase 3 clinical trials for major depressive disorder. Neumora is also working on treatments for Alzheimer's-related agitation, schizophrenia, Parkinson's Disease, Amyotrophic Lateral Sclerosis, and obesity. Founded in 2019, the company is led by CEO Dr. Joshua Pinto and employs 92 people.
Bottom Line
Needham's reiterated buy rating and $5.00 price target underscore the firm's confidence in Neumora's therapeutic pipeline. With ongoing developments and a volatile trading history, Neumora remains a stock to watch. As always, remember that 13F filings and analyst ratings reflect past performance and expectations, not current conditions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.